№ files_lp_4_process_3_123962
File format: docx
Character count: 6954
File size: 1122 KB
Detailed procedure for formalin-fixed, paraffin-embedded tissue immunostaining using antibody techniques for antigen retrieval and subsequent fluorescence detection in a laboratory setting.
Year:
2022
Region / city:
Minnesota, USA
Topic:
Immunohistochemistry
Document type:
Protocol
Author:
Lee Lab
Target audience:
Researchers and laboratory staff in immunohistochemistry
Period of validity:
Ongoing
Approval date:
Not specified
Date of revisions:
Not specified
Materials:
Xylene, Alcohols, DAPI, Hydrogen peroxide, Secondary antibodies, Reveal Decloaker, TRIS with tween, etc.
Equipment:
Fume hood, Gloves, Staining racks, Microscope slides, Coverslips, Microtome, Timer, etc.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / city:
Not specified
Topic:
Toxicity, drug efficacy
Document type:
Scientific figure
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, scientists
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Year
Document Type:
Guide Specification
Organization / Institution:
United Gilsonite Laboratories (UGL)
Target Audience:
Specifiers, Contractors
Related Documents:
Section 06 20 23, Section 06 40 23, Section 09 94 00
Referenced Standards:
ASTM D 16
Product Data:
ZAR® Oil-Base Stain, ZAR® Polyurethane
Qualification Requirements:
Manufacturer with 15+ years of experience, Applicator with 5+ years of experience
Environmental Conditions:
Apply above 50°F (10°C)
Project Conditions:
Store in clean, dry conditions
Products:
ZAR® Oil-Base Stain, ZAR® Polyurethane
Substitutions:
Not Permitted
Year:
2022
Region / City:
Not specified
Topic:
Parasitology, Laboratory Techniques
Document Type:
Instructional Guide
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Laboratory technicians, parasitologists
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Context
Year:
N/A
Region / City:
N/A
Subject:
Immunology
Document Type:
Research Supplement
Organization / Institution:
R&D Systems, ThermoFisher, Biolegend, Invitrogen, eBioscience
Author:
N/A
Target Audience:
Researchers in Immunology
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
NA
Region / City:
NA
Topic:
Clinical sample analysis
Document Type:
Research Data
Organization / Institution:
NA
Author:
NA
Target Audience:
NA
Period of Validity:
NA
Approval Date:
NA
Date of Changes:
NA
Contextual description:
Data presentation of patient samples analyzed by RT-qPCR, immunohistochemistry, and Western blot methods.
Year:
2014
Region / city:
Bethesda, MD
Topic:
Hematology, Immunohematology, Laboratory Procedures
Document Type:
Procedure Manual
Organization / Institution:
American Association of Blood Banks
Author:
Roback JD
Target Audience:
Laboratory personnel, medical professionals
Period of validity:
Ongoing, as of revision date
Approval Date:
March 1, 2014
Date of Changes:
March 1, 2014
References:
AABB Technical Manual, 17th ed., Methods in Immunhematology 3rd ed., Standards for Hospital Transfusion Services Version 3
Scope:
The document provides instructions for the removal of antibodies from coated red blood cells using freeze-thaw elution techniques, specifically for investigating ABO hemolytic disease of the fetus and newborn.
Year:
N/A
Region / City:
N/A
Topic:
Quality Control, Blood Grouping, Antibody Screening
Document Type:
Standard Operating Procedure
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Laboratory personnel involved in blood grouping and antibody screening
Period of validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2018
Disorder Type:
Neuro-inflammatory disease
Target:
Central nervous system
Symptoms:
Optic neuritis, spinal cord inflammation, demyelination
Diagnosis:
Positive MOG antibody test, MRI evidence of demyelination
Treatment:
Immunoglobulin therapy (IVIG/SCIG), other therapies as determined by physician
Prevalence:
1 per 500,000 people
References:
Fan S et al., 2018; Kezuka T & Ishikawa H, 2018; Dos Passos GR et al., 2018; Weber MS et al., 2018
Journal:
World Journal of Gastrointestinal Pathophysiology
Manuscript Type:
Original Article
Study Design:
Retrospective Cohort Study
Authors:
Hyun Ah Chung; Sun-Young Lee; Hee Won Moon; Jeong Hwan Kim; In-Kyung Sung; Hyung Seok Park; Chan Sup Shim; Hye Seung Han
Affiliations:
Department of Internal Medicine, Department of Laboratory Medicine, and Department of Pathology, Konkuk University School of Medicine, Seoul 05030, South Korea
Corresponding Author:
Sun-Young Lee, MD, PhD
Country:
South Korea
Funding:
Supported by Konkuk University in 2015 (No. KU2015-A019-0270)
Institutional Review Board Approval:
Konkuk University School of Medicine (KUH1010625)
Clinical Trial Registration:
ClinicalTrials.gov ID: KCT0001302
Received:
December 27, 2015
Accepted:
July 11, 2016
Publication Year:
2016
Keywords:
Antibody; Helicobacter pylori; Hepatitis B; Immunoglobulin G; Pepsinogen
License:
Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
Year:
2023
Region / City:
Not specified
Topic:
Anti-nuclear antibody testing, technical issues
Document type:
Update
Author:
Dr. Anna McHugh
Target audience:
Healthcare professionals
Action period:
May 2023
Approval date:
Not specified
Change date:
16th May 2023
Context:
The document is an update on delays and technical issues with anti-nuclear antibody testing, outlining the steps being taken to resolve the situation and advising healthcare professionals on necessary actions for patients.
Year:
2024
Region / city:
Hull, United Kingdom
Topic:
Coeliac Disease Screening
Document Type:
Medical Guidelines
Organization:
NHS
Author:
Anna McHugh
Target Audience:
Healthcare Professionals
Period of Validity:
From January 2023
Approval Date:
Not specified
Date of Changes:
February 2024
Year:
2023
Region / City:
Not specified
Topic:
Monoclonal antibody sequences, growth rate inhibition in cell models
Document type:
Research Supplementary Material
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Researchers, biomedical professionals
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2012
Region / City:
United Kingdom
Subject:
Blood Grouping, Red Cell Antibody Testing, Pregnancy
Document Type:
Audit Tool
Institution:
British Committee for Standards in Haematology (BCSH)
Author:
N/A
Target Audience:
Healthcare professionals involved in blood transfusion, obstetrics, and fetal medicine
Period of Application:
Ongoing
Date of Approval:
N/A
Date of Changes:
N/A
Year:
2021
Region / city:
Various locations in the United States
Topic:
COVID-19 Treatment
Document type:
Clinical Trial Report
Institution:
Regeneron Pharmaceuticals, NIAID/CoVPN
Author:
Multiple investigators and research teams
Target audience:
Healthcare professionals, researchers, clinical trial coordinators
Period of validity:
Study conducted during 2020-2021
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Canada, multiple cities
Subject:
COVID-19 treatment eligibility
Document Type:
Medical referral form
Organization / Institution:
Health Canada; regional hospitals
Author:
Clinicians completing referral
Target Audience:
Healthcare providers and eligible patients
Eligibility Criteria:
Adults and pediatric patients ≥12 years, ≥40 kg, at high risk of severe COVID-19
Treatment Window:
Within 7 days of symptom onset
Authorization:
Interim authorization (Interim Order) by Health Canada
Patient Data Fields:
Name, Date of birth, Allergies, Address, Contact information, Health Card Number
Clinical Criteria:
Symptomatic status, vaccination status, comorbidities, immunosuppression, prior COVID-19 infection
Referral Confirmation:
Clinician attestation with signature, date, and College number
Year:
2023
Region / city:
Rockville, MD, United States; Ottawa, ON, Canada
Topic:
NMR assignments, antibody research, protein expression
Document type:
Research article
Institution:
Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, University of Maryland; Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiotherapeutic Drugs Directorate, Health Canada
Author:
Tsega L. Solomon, Kinlin Chao, Genevieve Gingras, Yves Aubin, William B. O’Dell, John P. Marino, Robert G. Brinson
Target audience:
Researchers in biochemistry, protein chemistry, pharmaceutical sciences
Effective period:
2023 and onwards
Approval date:
N/A
Date of changes:
N/A
Keywords:
backbone assignments, Fab domain, NISTmAb, biologics, monoclonal antibodies
Context description:
This document presents the results of a study on the backbone NMR assignments of the yeast-expressed Fab fragment of the NISTmAb antibody, aimed at advancing structural characterization techniques for monoclonal antibodies.
Instrument:
Immucor Galileo Echo
Test Panels:
Capture-R Ready-ID; Capture-R Extend I; Capture-R Extend II
Test Method:
IgG antibody panel using Capture-R technology
Temperature:
37°C
Specimen Type:
EDTA anticoagulated whole blood; serum from fully clotted blood
Specimen Stability:
≤5 days from collection; ≤4 days for recently transfused or pregnant patients
Exclusion Criteria:
Hemolyzed (≥3+), lipemic, or icteric samples not accepted
Reagents:
Capture LISS; Capture-R Ready-ID; Capture-R Extend I & Extend II; Capture-R Indicator Cells; WB corQC; PHIX buffered saline
Equipment:
Immucor Galileo Echo
Quality Control:
Commercial WB corQC performed daily; 24-hour control interval after validation
Controls:
Positive and negative controls included in each 14-cell panel
Related Policy:
SWIM manual NRT.007 “Antibody Identification of Warm Reactive Antibodies”
Reporting:
Results reviewed and confirmed by technologist; specimens forwarded for additional antibody testing if required
Restrictions:
Partially used strips cannot be reused
References:
Galileo Echo Operator Manual; SWIM manual
Year:
2022
Region / City:
Belfast
Subject:
COVID-19, SARS-CoV-2, antibody neutralisation
Document type:
Research study call
Organization / Institution:
Queen’s University Belfast
Author:
Ultan Power
Target audience:
Healthy volunteers aged 18-65
Study period:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / city:
Not specified
Topic:
Recombinant proteins, antibodies, and reagents for macrophage polarization and related techniques
Document type:
Laboratory protocol
Institution:
Not specified
Author:
Not specified
Target audience:
Researchers in molecular biology and immunology
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified